‘A Fuse Burning At Both Ends’: German Near-Term Market Outlook For Medtech Industry
Report on medtech’s new hurdles in Europe makes for sobering reading
Later market launch of innovations and a hit on EBITDA are simultaneously affecting medtech companies in Germany and central Europe as they strive to keep quality uppermost while battling the most frustrating confluence of negative effects on business than most companies have ever seen.
You may also be interested in...
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.
After an admittedly difficult 2022 for a variety of reasons, Philips Healthcare is ready to tackle 2023 and beyond by reducing business complexities, slimming staff numbers further and crucially implementing a new value creation strategy under recently appointed CEO Roy Jakobs.
Interested parties have been consulted, workshop findings noted and online surveys completed; the drafting of Germany’s digital health strategy is now underway.